{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:38:12Z","timestamp":1793032692240,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ijpx.2026.100663","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:28:02Z","timestamp":1789086482000},"page":"100663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From prediction to performance: In silico-supported formulation of amorphous solid dispersions for PROTAC NX-2127"],"prefix":"10.1016","volume":"12","author":[{"given":"Alicia","family":"Stakemeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Mild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Kalasov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina E.","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kuentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steinebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl G.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ph12010015","article-title":"Micellisation mechanism and behaviour of Soluplus\u00ae\u2013furosemide micelles: preformulation studies of an oral nanocarrier-based system","volume":"12","author":"Alopaeus","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijpx.2026.100663_bb0010","doi-asserted-by":"crossref","first-page":"118352","DOI":"10.1016\/j.biopha.2025.118352","article-title":"Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines","volume":"189","author":"Arenas-Moreira","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijpx.2026.100663_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejpb.2016.06.024","article-title":"Theoretical and experimental investigation of drug-polymer interaction and miscibility and its impact on drug supersaturation in aqueous medium","volume":"107","author":"Baghel","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100663_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejpb.2016.06.015","article-title":"Micro-scale prediction method for API-solubility in polymeric matrices and process model for forming amorphous solid dispersion by hot-melt extrusion","volume":"107","author":"Bochmann","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.ijpx.2026.100663_bb0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/jps.2600600902","article-title":"Pharmaceutical applications of solid dispersion systems","volume":"60","author":"Chiou","year":"1971","journal-title":"J. Pharm. Sci."},{"issue":"21","key":"10.1016\/j.ijpx.2026.100663_bb0030","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1021\/acs.iecr.4c00652","article-title":"Using molecular conformers in COSMO-RS to predict drug solubility in mixed solvents","volume":"63","author":"Cordova","year":"2024","journal-title":"Ind. Eng. Chem. Res."},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1021\/ma60061a021","article-title":"A classical thermodynamic discussion of the effect of composition on glass-transition temperatures","volume":"11","author":"Couchman","year":"1978","journal-title":"Macromolecules"},{"issue":"Supplement 1","key":"10.1016\/j.ijpx.2026.100663_bb0040","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton\u2019s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ijpx.2026.100663_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/pharmaceutics12030237","article-title":"A rational design of a biphasic dissolution setup\u2014modelling of biorelevant kinetics for a Ritonavir hot-melt extruded amorphous solid dispersion","volume":"12","author":"Denninger","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ijpx.2026.100663_bb0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/pharmaceutics13020285","article-title":"Shared IVIVR for five commercial enabling formulations using the BiPHa+ biphasic dissolution assay","volume":"13","author":"Denninger","year":"2021","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.ijpx.2026.100663_bb0055","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijpx.2026.100663_bb0060","author":"EMA"},{"issue":"16","key":"10.1016\/j.ijpx.2026.100663_bb0065","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/molecules26164964","article-title":"Preparation of curcumin-Eudragit\u00ae E PO solid dispersions with gradient temperature through hot-melt extrusion","volume":"26","author":"Fan","year":"2021","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.ijpx.2026.100663_bb0070","doi-asserted-by":"crossref","first-page":"e70401","DOI":"10.1002\/mco2.70401","article-title":"Proteolysis-targeting chimera (PROTAC): current applications and future directions","volume":"6","author":"Fan","year":"2025","journal-title":"MedComm"},{"issue":"19","key":"10.1016\/j.ijpx.2026.100663_bb0075","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing soluble PROTACs: strategies and preliminary guidelines","volume":"65","author":"Garc\u00eda Jim\u00e9nez","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ijpx.2026.100663_bb0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jctb.5010020901","article-title":"Ideal copolymers and the second-order transitions of synthetic rubbers. i. non-crystalline copolymers","volume":"2","author":"Gordon","year":"1952","journal-title":"J. Appl. Chem."},{"issue":"4","key":"10.1016\/j.ijpx.2026.100663_bb0085","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/ijms26041499","article-title":"Soluplus\u00ae-based pharmaceutical formulations: recent advances in drug delivery and biomedical applications","volume":"26","author":"Guembe-Michel","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijpx.2026.100663_bb0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1039\/C1MD00017A","article-title":"Molecular obesity, potency and other addictions in drug discovery","volume":"2","author":"Hann","year":"2011","journal-title":"MedChemComm"},{"key":"10.1016\/j.ijpx.2026.100663_bb0095","doi-asserted-by":"crossref","first-page":"100423","DOI":"10.1016\/j.mtbio.2022.100423","article-title":"Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles","volume":"16","author":"He","year":"2022","journal-title":"Mater. Today Bio"},{"issue":"16","key":"10.1016\/j.ijpx.2026.100663_bb0100","doi-asserted-by":"crossref","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","article-title":"Radioactive ADME demonstrates ARV-110\u2019s high druggability despite low oral bioavailability","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpx.2026.100663_bb0105","doi-asserted-by":"crossref","first-page":"123725","DOI":"10.1016\/j.ijpharm.2023.123725","article-title":"ASDs of PROTACs: spray-dried solid dispersions as enabling formulations","volume":"650","author":"Hofmann","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ijpx.2026.100663_bb0110","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1021\/acs.molpharmaceut.5c00303","article-title":"PROTAC enabling formulation in vivo: implications of the polymeric carrier Eudragit E PO","volume":"22","author":"Hofmann","year":"2025","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.ijpx.2026.100663_bb0115","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijpx.2026.100663_bb0120","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1208\/s12249-014-0252-2","article-title":"Interpolyelectrolyte complexes of Eudragit\u00ae EPO with hypromellose acetate succinate and Eudragit\u00ae EPO with hypromellose phthalate as potential carriers for oral controlled drug delivery","volume":"16","author":"Jeganathan","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2026.100663_bb0125","article-title":"Effective degradation of wild-type and mutant EGFR using self-assembling peptide-derived PROTAC nanoparticles (NanoTACs) for cancer therapy","author":"Jeong","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijpx.2026.100663_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127841","article-title":"In silico cocrystal screening using COSMO-RS: a rapid and efficient approach for solubility prediction and crystal engineering","volume":"433","author":"Jha","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ijpx.2026.100663_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126200","article-title":"High-throughput analysis of aqueous drug solubility, supersaturation, and aggregation behaviour using second harmonic light scattering","volume":"685","author":"Kalasov\u00e1","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100663_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.102923","article-title":"Interspecies differences in gastrointestinal physiology affecting the in vivo performance of oral pharmaceutical solid dosage forms","volume":"67","author":"Kambayashi","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"5","key":"10.1016\/j.ijpx.2026.100663_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12272-025-01546-0","article-title":"BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies","volume":"48","author":"Kim","year":"2025","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.ijpx.2026.100663_bb0150","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/j100007a062","article-title":"Conductor-like screening model for real solvents: a new approach to the quantitative calculation of solvation phenomena","volume":"99","author":"Klamt","year":"1995","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.ijpx.2026.100663_bb0155","series-title":"Analytik [Internet]","author":"K\u00fcster","year":"2023"},{"key":"10.1016\/j.ijpx.2026.100663_bb0160","series-title":"Rdkit Documentation","first-page":"1","volume":"1(4)","author":"Landrum","year":"2013"},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","article-title":"Improving drug solubility for oral delivery using solid dispersions","volume":"50","author":"Leuner","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.ijpx.2026.100663_bb0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-018-2408-3","article-title":"Physical stability of amorphous solid dispersions: a physicochemical perspective with thermodynamic, kinetic and environmental aspects","volume":"35","author":"Lin","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100663_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100663_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120648","article-title":"The relevance of supersaturation and solubilization in the gastrointestinal tract for oral bioavailability: an in vitro vs. in vivo approach","volume":"603","author":"L\u00f3pez M\u00e1rmol","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"43","key":"10.1016\/j.ijpx.2026.100663_bb0185","doi-asserted-by":"crossref","first-page":"14303","DOI":"10.1021\/ie3023675","article-title":"COSMO quick\u00a0: a novel interface for fast \u03c3-profile composition and its application to COSMO-RS solvent screening using multiple reference solvents","volume":"51","author":"Loschen","year":"2012","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.ijpx.2026.100663_bb0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcis.2021.12.016","article-title":"Understanding the self-assembly of the polymeric drug solubilizer Soluplus\u00ae","volume":"611","author":"Mateos","year":"2022","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijpx.2026.100663_bb0195","article-title":"Unlocking the potential of alkaline polymethacrylates via ionic crosslinking in amorphous solid dispersions","volume":"11","author":"Mild","year":"2026","journal-title":"Int J Pharm X"},{"issue":"6682","key":"10.1016\/j.ijpx.2026.100663_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ijpx.2026.100663_bb0205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejps.2013.08.018","article-title":"Animal versus human oral drug bioavailability: do they correlate?","volume":"57","author":"Musther","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100663_bb0210","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijpx.2026.100663_bb0215","first-page":"114719","article-title":"A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats","volume":"211","author":"Niessen","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ijpx.2026.100663_bb0220","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1021\/acs.molpharmaceut.6c00207","article-title":"The in vivo effect of amorphous drug nanoprecipitates on the intestinal absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant)","volume":"23","author":"Niessen","year":"2026","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.ijpx.2026.100663_bb0225","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s13346-022-01182-x","article-title":"Soluplus\u00ae polymeric nanomicelles improve solubility of BCS-class II drugs","volume":"12","author":"Pignatello","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"10","key":"10.1016\/j.ijpx.2026.100663_bb0230","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.ijpx.2026.100663_bb0240","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/acsomega.2c07717","article-title":"Predictive modeling of PROTAC cell permeability with machine learning","volume":"8","author":"Poongavanam","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0245","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/pharmaceutics15010156","article-title":"Solubility enhanced formulation approaches to overcome oral delivery obstacles of PROTACs","volume":"15","author":"P\u00f6stges","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ijpx.2026.100663_bb0250","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/acs.molpharmaceut.5b00655","article-title":"Role of molecular interactions for synergistic precipitation inhibition of poorly soluble drug in supersaturated drug\u2013polymer\u2013polymer ternary solution","volume":"13","author":"Prasad","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100663_bb0255","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejps.2019.03.006","article-title":"Calculation of drug-polymer mixing enthalpy as a new screening method of precipitation inhibitors for supersaturating pharmaceutical formulations","volume":"132","author":"Price","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ijpx.2026.100663_bb0260","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/pharmaceutics14091830","article-title":"Enteric polymer\u2013based amorphous solid dispersions enhance oral absorption of the weakly basic drug Nintedanib via stabilization of supersaturation","volume":"14","author":"Qin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100663_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105039","article-title":"BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: preformulation studies, formulation development and in vitro evaluation","volume":"138","author":"Rathod","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ijpx.2026.100663_bb0270","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton\u2019s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ijpx.2026.100663_bb0275","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"18","key":"10.1016\/j.ijpx.2026.100663_bb0280","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","article-title":"Nanoformulation of PROteolysis targeting Chimera TArgeting \u2018undruggable\u2019 C-Myc for the treatment of pancreatic cancer","volume":"15","author":"Saraswat","year":"2020","journal-title":"Nanomed"},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08702","article-title":"Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy","volume":"8","author":"Saraswat","year":"2022","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.ijpx.2026.100663_bb0290","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1021\/acs.molpharmaceut.5c01107","article-title":"Developing multi-component solid formulation strategies for PROTAC dissolution enhancement","volume":"22","author":"Screen","year":"2025","journal-title":"Mol. Pharm."},{"issue":"31","key":"10.1016\/j.ijpx.2026.100663_bb0295","doi-asserted-by":"crossref","first-page":"28056","DOI":"10.1021\/jacs.5c07977","article-title":"Crystallizing the uncrystallizable: insights from extensive screening of PROTACs","volume":"147","author":"Screen","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.ijpx.2026.100663_bb0300","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3390\/pharmaceutics12111019","article-title":"Vacuum compression molding as a screening tool to investigate carrier suitability for hot-melt extrusion formulations","volume":"12","author":"Shadambikar","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ijpx.2026.100663_bb0305","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acs.jmedchem.5c00358","article-title":"In vitro ADME profiling of PROTACs: successes, challenges, and lessons learned from analysis of clinical PROTACs from a diverse physicochemical space","volume":"68","author":"Srivastava","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ijpx.2026.100663_bb0310","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1021\/mp400439q","article-title":"Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation","volume":"10","author":"Sun","year":"2013","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.ijpx.2026.100663_bb0315","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.xphs.2016.03.024","article-title":"Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems","volume":"105","author":"Sun","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ijpx.2026.100663_bb0320","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ijpx.2026.100663_bb0325","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/mp700095p","article-title":"Characterization of gastrointestinal drug absorption in cynomolgus monkeys","volume":"5","author":"Takahashi","year":"2008","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.ijpx.2026.100663_bb0330","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/pharmaceutics14102203","article-title":"Recent advances in amorphous solid dispersions: preformulation, formulation strategies, technological advancements and characterization","volume":"14","author":"Tambe","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/ct5008857","article-title":"Validation of the direct-COSMO-RS solvent model for Diels\u2013Alder reactions in aqueous solution","volume":"11","author":"Theilacker","year":"2015","journal-title":"J. Chem. Theory Comput."},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0345","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1038\/s41467-025-65478-5","article-title":"Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC","volume":"16","author":"Torodii","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijpx.2026.100663_bb0350","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2015.09.001","article-title":"A novel tool to standardize rheology testing of molten polymers for pharmaceutical applications","volume":"495","author":"Treffer","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100663_bb0355","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2016.01.012","article-title":"Amorphous solid dispersions: rational selection of a manufacturing process","volume":"100","author":"Vasconcelos","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ijpx.2026.100663_bb0360","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpx.2026.100663_bb0365","author":"Wang"},{"issue":"8","key":"10.1016\/j.ijpx.2026.100663_bb0370","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijpx.2026.100663_bb0375","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17460441.2023.2187047","article-title":"Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs)","volume":"18","author":"Yokoo","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.ijpx.2026.100663_bb0380","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jps.23592","article-title":"Rational development of solid dispersions via hot-melt extrusion using screening, material characterization, and numeric simulation tools","volume":"102","author":"Zecevic","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ijpx.2026.100663_bb0385","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s42114-023-00649-w","article-title":"Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities","volume":"6","author":"Zhang","year":"2023","journal-title":"Adv. Compos. Hybrid Mater."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:01:24Z","timestamp":1793030484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":75,"alternative-id":["S2590156726001830"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100663","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From prediction to performance: In silico-supported formulation of amorphous solid dispersions for PROTAC NX-2127","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100663"}}